Dartmouth Hitchcock Dermatology Clinic
Welcome,         Profile    Billing    Logout  
 0 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Simmons, Brian
NCT06569537: Comparison of Compounded Topical Anesthetics

Recruiting
4
60
US
Lidocaine topical, BLT
Dartmouth-Hitchcock Medical Center
Procedural Pain
09/26
09/26
ADorable-1, NCT05559359: A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Recruiting
3
300
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, DRM06, Placebo, Topical corticosteroid
Eli Lilly and Company, Dermira, Inc.
Atopic Dermatitis, Eczema
05/25
09/25
TAK-279-PsO-3003, NCT06550076: A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
3
1300
Europe, Canada, Japan, US, RoW
TAK-279
Takeda
Plaque Psoriasis
05/26
05/26
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Active, not recruiting
3
693
Europe, Canada, Japan, US, RoW
TAK-279, Placebo, Apremilast
Takeda
Plaque Psoriasis
08/25
04/26
ADorable-2, NCT05735483: A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Enrolling by invitation
3
250
Europe, Canada, Japan, US, RoW
Lebrikizumab, LY3650150, Placebo
Eli Lilly and Company
Atopic Dermatitis, Eczema
06/26
06/26
NCT05821374: Deucravacitinib in PG

Not yet recruiting
1
10
US
Deucravacitinib, SOTYKTU
Dartmouth-Hitchcock Medical Center, Bristol-Myers Squibb
Pyoderma Gangrenosum
11/25
01/26
Awad, Nardin
NCT06569537: Comparison of Compounded Topical Anesthetics

Recruiting
4
60
US
Lidocaine topical, BLT
Dartmouth-Hitchcock Medical Center
Procedural Pain
09/26
09/26

Download Options